https://www.selleckchem.com/products/CHIR-258.html
When she developed progression on conventional chemotherapy, a trial of T. Erlotinib was given (since patient was a nonsmoker woman). Within a month, patient reported significant improvement in the dyspnea and did not require nebulization. 18F-FDG PET/CT was repeated after ~6 months, which showed significant response to the oral erlotinib monotherapy. Patient was doing well at 1-year follow-up, with only dermatological adverse effects (rashes). We reported the case of a 76-year-old man followed up since 2008 for a prostatic adenocarcin
Like
Comment
Share
